

Apostle Inc Appoints Antonius ‘Toni’ Schuh to Board of Advisors

For immediate release

MENLO PARK, CA, January 27, 2020 – Apostle Inc is pleased to announce the appointment of Antonius ‘Toni’ Schuh, PhD as a new member to its Board of Advisors. Toni is a successful serial entrepreneur and founder in the biotechnology, healthcare and life sciences industries, and has served as CEO of five life sciences companies with three IPOs. Currently a founder of Global Source Ventures, he has over 20 years of executive leadership and founding experience including Arcturus Bioscience, AviraDx (now bioTheranostics), Sequenom (NASDAQ: SQNM), Sorrento Therapeutics (NASDAQ: SRNE) and Trovagene (NASDAQ: TROV). In each case he developed the company’s strategy based on a focused value proposition, oversaw the execution of such strategy, and secured funding to achieve transforming milestones, including multiple product launches. He delivered significant returns for investors at exit (public offering or acquisition). Toni is a certified pharmacist and earned his Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany.



“I’m thrilled and thankful to welcome Toni to our Board of Advisors,” said David Ge, CEO of Apostle. “Toni is a legendary serial entrepreneur. His advice will add tremendous value to our company and guide us as we further our mission of bringing innovative technologies to liquid biopsy and its applications.”

About Apostle Inc

Apostle Inc is a biotechnology company in Menlo Park, CA, aiming to develop innovative technologies in the space of liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing circulating free DNA (cfDNA) as a biomarker. Apostle’s innovations include Apostle MiniMax™, a new scalable and automatable method to efficiently capture cfDNA from a standard blood draw.

More information can be found at www.apostlebio.com.

Contact: info@apostlebio.com